Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

June 1, 2016 | Author: Edgar Raul Lazo Cordero | Category: N/A

Embed

Donate

Report this link

Description

Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg[#60 kg], 45 mg [[60-#100 kg], a...

Comments

SUPPORT DOCURI

We need your help!

Thank you for interesting in our services. We are a non-profit group that run this website to share documents. We need your help to maintenance this website.

Donate
Sharing

To keep our site running, we need your help to cover our server cost (about $400/m), a small donation will help us a lot.

No, thanks! Close the box.